Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
An in-depth analysis of pharma and healthcare industry trends in H2 2025,…
Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for pertussis vax
Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for…
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B Professional…
Public Health Video Recap—December 19, 2025
This biweekly Public Health video recap highlights breakthroughs in vaccine…
How we supported a leading vaccine company in restructuring its global organization.
The Challenge: How to successfully lead restructuring in many geographies A…
RSV vaccines: A powerful tool to protect against RSV
According tο a recent systematic analysis focusing on children younger than…
The future of Dengue vaccines
According to a WHO 2019 statement, Dengue fever is considered one of the top 10…
The sleeping giant of nanomedicine
Nanomedicine applies the tools and knowledge of nanotechnology for the…
Should we trust vaccines or not?
The first COVID-19 vaccines have been administered in several countries around…
When it comes to COVID-19, a “nose job” might do the trick
Injectable COVID-19 vaccines may not be the only preventative measure against…
Human impact on the environment and the risk of developing disease
The human impact on the environment is expected to have complex effects on…
